Nasonex

Effective July 27, 2017, Nasonex will be reclassified from preferred to non-preferred. Fluticasone nasal will be the only preferred intranasal corticosteroid for allergic rhinitis. Patients requiring Nasonex on or after July 27, 2017 will require a prior authorization. Prior authorization forms can be found here: https://www.navitus.com/texas-medicaid-starchip/prior-authorization-forms.aspxQuestions? Please contact Navitus at 1-877-908-6023.